ScholarMate
客服热线:400-1616-289
登录注册

Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma.

Gu Jingli; Liu Junru; Chen Meilan; Huang Beihui; Li Juan
OTHER
中山大学学院
引用 分享 收藏

全文

请求全文

请求全文

摘要

Many questions about minimal residual disease (MRD) still need to be answered for multiple myeloma (MM). Flow MRD was monitored in 104 consecutive patients with MM after induction and at the 3rd, 6th, 9th, 12th, 18th, and 24th months post-transplant. Four MRD evolution patterns were revealed: Pattern 1 patients had persistent MRD-negative status after post-induction with no progression; pattern 2 patients had MRD-positive status postinduction but became MRD negative within 24 months post-transplant; pattern 3 patients had MRD-negative status postinduction but became MRD positive within 24 months post-transplant; and pattern 4 patients had persistent MRD-positive status after postinduction. Patients with MRD evolution pattern 1 had a better time to progression than did patients with the other evolution patterns (not reached versus not reached, versus 15.4 /- 2.4 months, versus 16.9 /- 3.0 months; log-rank test, P=.003, P=.000, and P=.000, respectively). Patients with MRD pattern 1 had a significantly longer overall survival than did patients with pattern 3 (not reached versus 35.2 /- 18.6 months; log-rank test, P=.000) and pattern 4 (not reached versus 23.8 /- 15.0 months, log-rank test, P=.000) but had a similar overall survival as pattern 2 patients (not reached versus not reached; log-rank test, P=.229). For progressing patients with MRD evolution pattern 2 or 3, the median interval of a sustained MRD-negative status was only 17 months and the median time from MRD reappearance to disease progression was only 4.6 months. A more complete MRD evolution pattern was developed to predict the outcomes for patients with MM. The optimal time of MRD assessment should include postinduction and 3rd and 24th month post-transplant. Regular MRD assessments will help detect relapse early. A sustained negative MRD status should last for at least 24 months.

关键词

Autologous stem cell transplantationMinimal residual diseaseMultiple myelomaPrognosis

出版信息

论文状态
公开发表
期刊名称
Biol Blood Marrow Transplant
发表日期
2018-12
卷
24
期
12
页码
2568-2574
DOI
10.1016/j.bbmt.2018.07.040

学科领域

-

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【立即咨询】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417